Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs

Breast cancer (BC) is the most frequent cancer in women. In female dogs, canine mammary gland tumor (CMT) is also the leading neoplasm. Comparative oncology indicates similar tumor behaviors between human BCs (HBCs) and CMTs. Therefore, this review summarizes the current research in hormone and targ...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 25; no. 2; p. 732
Main Authors Ke, Chiao-Hsu, Lin, Chao-Nan, Lin, Chen-Si
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.01.2024
Subjects
Animals
Antibodies, Monoclonal - therapeutic use
Antimitotic agents
Antineoplastic agents
Autophagy
Biological products
Breast cancer
Breast Neoplasms - drug therapy
Canada
Cancer
Cancer therapies
Care and treatment
Clinical trials
Combined Modality Therapy
Comparative analysis
Development and progression
Dogs
Drug resistance
Endocrine therapy
Endometrial cancer
Estrogens
Female
Females
Health aspects
Hormones
Human acts
Human behavior
Humans
Kinases
Ligands
Monoclonal antibodies
Mortality
Oncology
Prospective Studies
Steroid hormones
Steroids
Taiwan
Toxicity
Tumors
Canada
Taiwan
targeted therapy
hormone therapy
canine mammary gland tumor
comparative oncology
Online AccessGet full text

Cover

Abstract Breast cancer (BC) is the most frequent cancer in women. In female dogs, canine mammary gland tumor (CMT) is also the leading neoplasm. Comparative oncology indicates similar tumor behaviors between human BCs (HBCs) and CMTs. Therefore, this review summarizes the current research in hormone and targeted therapies and describes the future prospects for HBCs and CMTs. For hormone receptor-expressing BCs, the first medical intervention is hormone therapy. Monoclonal antibodies against Her2 are proposed for the treatment of Her2+ BCs. However, the major obstacle in hormone therapy or monoclonal antibodies is drug resistance. Therefore, increasing alternatives have been developed to overcome these difficulties. We systemically reviewed publications that reported inhibitors targeting certain molecules in BC cells. The various treatment choices for humans decrease mortality in females with BC. However, the development of hormone or targeted therapies in veterinary medicine is still limited. Even though some clinical trials have been proposed, severe side effects and insufficient case numbers might restrict further explorations. This difficulty highlights the urgent need to develop updated hormone/targeted therapy or novel immunotherapies. Therefore, exploring new therapies to provide more precise use in dogs with CMTs will be the focus of future research. Furthermore, due to the similarities shared by humans and dogs, well-planned prospective clinical trials on the use of combinational or novel immunotherapies in dogs with CMTs to obtain solid results for both humans and dogs can be reasonably anticipated in the future.
AbstractList Breast cancer (BC) is the most frequent cancer in women. In female dogs, canine mammary gland tumor (CMT) is also the leading neoplasm. Comparative oncology indicates similar tumor behaviors between human BCs (HBCs) and CMTs. Therefore, this review summarizes the current research in hormone and targeted therapies and describes the future prospects for HBCs and CMTs. For hormone receptor-expressing BCs, the first medical intervention is hormone therapy. Monoclonal antibodies against Her2 are proposed for the treatment of Her2+ BCs. However, the major obstacle in hormone therapy or monoclonal antibodies is drug resistance. Therefore, increasing alternatives have been developed to overcome these difficulties. We systemically reviewed publications that reported inhibitors targeting certain molecules in BC cells. The various treatment choices for humans decrease mortality in females with BC. However, the development of hormone or targeted therapies in veterinary medicine is still limited. Even though some clinical trials have been proposed, severe side effects and insufficient case numbers might restrict further explorations. This difficulty highlights the urgent need to develop updated hormone/targeted therapy or novel immunotherapies. Therefore, exploring new therapies to provide more precise use in dogs with CMTs will be the focus of future research. Furthermore, due to the similarities shared by humans and dogs, well-planned prospective clinical trials on the use of combinational or novel immunotherapies in dogs with CMTs to obtain solid results for both humans and dogs can be reasonably anticipated in the future.
Breast cancer (BC) is the most frequent cancer in women. In female dogs, canine mammary gland tumor (CMT) is also the leading neoplasm. Comparative oncology indicates similar tumor behaviors between human BCs (HBCs) and CMTs. Therefore, this review summarizes the current research in hormone and targeted therapies and describes the future prospects for HBCs and CMTs. For hormone receptor-expressing BCs, the first medical intervention is hormone therapy. Monoclonal antibodies against Her2 are proposed for the treatment of Her2+ BCs. However, the major obstacle in hormone therapy or monoclonal antibodies is drug resistance. Therefore, increasing alternatives have been developed to overcome these difficulties. We systemically reviewed publications that reported inhibitors targeting certain molecules in BC cells. The various treatment choices for humans decrease mortality in females with BC. However, the development of hormone or targeted therapies in veterinary medicine is still limited. Even though some clinical trials have been proposed, severe side effects and insufficient case numbers might restrict further explorations. This difficulty highlights the urgent need to develop updated hormone/targeted therapy or novel immunotherapies. Therefore, exploring new therapies to provide more precise use in dogs with CMTs will be the focus of future research. Furthermore, due to the similarities shared by humans and dogs, well-planned prospective clinical trials on the use of combinational or novel immunotherapies in dogs with CMTs to obtain solid results for both humans and dogs can be reasonably anticipated in the future.Breast cancer (BC) is the most frequent cancer in women. In female dogs, canine mammary gland tumor (CMT) is also the leading neoplasm. Comparative oncology indicates similar tumor behaviors between human BCs (HBCs) and CMTs. Therefore, this review summarizes the current research in hormone and targeted therapies and describes the future prospects for HBCs and CMTs. For hormone receptor-expressing BCs, the first medical intervention is hormone therapy. Monoclonal antibodies against Her2 are proposed for the treatment of Her2+ BCs. However, the major obstacle in hormone therapy or monoclonal antibodies is drug resistance. Therefore, increasing alternatives have been developed to overcome these difficulties. We systemically reviewed publications that reported inhibitors targeting certain molecules in BC cells. The various treatment choices for humans decrease mortality in females with BC. However, the development of hormone or targeted therapies in veterinary medicine is still limited. Even though some clinical trials have been proposed, severe side effects and insufficient case numbers might restrict further explorations. This difficulty highlights the urgent need to develop updated hormone/targeted therapy or novel immunotherapies. Therefore, exploring new therapies to provide more precise use in dogs with CMTs will be the focus of future research. Furthermore, due to the similarities shared by humans and dogs, well-planned prospective clinical trials on the use of combinational or novel immunotherapies in dogs with CMTs to obtain solid results for both humans and dogs can be reasonably anticipated in the future.
Audience Academic
Author Lin, Chao-Nan
Lin, Chen-Si
Ke, Chiao-Hsu
Author_xml – sequence: 1
  givenname: Chiao-Hsu
  orcidid: 0000-0001-9602-9630
  surname: Ke
  fullname: Ke, Chiao-Hsu
– sequence: 2
  givenname: Chao-Nan
  orcidid: 0000-0003-1911-7535
  surname: Lin
  fullname: Lin, Chao-Nan
– sequence: 3
  givenname: Chen-Si
  orcidid: 0000-0003-2254-8344
  surname: Lin
  fullname: Lin, Chen-Si
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38255807$$D View this record in MEDLINE/PubMed
BookMark eNptkU1PGzEQhq0qFQHKrefKUi8cEvDHeu30lgZokJB6iXpdee1xcLS2U3v3wL_vBigfVTWHGY2eeUcz7wmaxBQBoc-UXHC-IJd-FwoThBHJ2Qd0TCvG5oTUcvKmnqKTUnaEMM7E4ghNuWJCKCKP0a91ymEUnOGNzlvowc6wjhavUmh91L1PUXd4cw9Z7z0U7FLG3zPo0uOVjgZy-YZvcgp4PQQdC-4Tvkrb8gl9dLorcPacT9Hm5nqzWs_vfv64XS3v5oYr2s8FY5WrRC0Uta2lwvJWGGaNIUZB7RzUVb0g3FlaGQKagTLKtE4aCZIpyk_R-ZPsPqffA5S-Cb4Y6DodIQ2lYQsqVV1TRUb06z_oLg15PO6RUrJWSrJXaqs7aHx0qc_aHESbpVRkxCp6WHvxH2oMC8Gb8ZvOj_13A1-elw9tANvssw86PzR_fRiB2RNgciolg3tBKGkONjdvbeZ_AHV4lxQ
Cites_doi 10.1210/en.2015-1392
10.1016/S1470-2045(15)00551-3
10.1186/s12885-015-1583-4
10.1158/0008-5472.CAN-05-1182
10.1038/nrd4360
10.1158/1538-7445.SABCS20-PD1-11
10.1093/annonc/mdz192
10.1186/s12917-021-03093-4
10.1093/jnci/djv048
10.1056/NEJMoa064320
10.1007/s10549-017-4548-2
10.1016/S0140-6736(02)09088-8
10.1038/s41467-020-17458-0
10.1001/jama.2018.19323
10.1093/annonc/mdz012
10.1177/0300985810389480
10.1200/JCO.19.00368
10.1093/annonc/mdw320
10.1001/jama.2016.18305
10.1186/s12964-019-0450-3
10.1158/1535-7163.MCT-09-1171
10.1007/s10549-018-5023-4
10.1111/j.1476-5829.2009.00184.x
10.1007/s11912-019-0846-7
10.1016/j.molimm.2012.01.002
10.1186/s12885-018-4518-z
10.2217/fon.14.110
10.1177/1758834015608993
10.1210/endo-105-2-431
10.1056/NEJMoa052258
10.1186/s13046-022-02515-x
10.1158/1078-0432.CCR-22-0305
10.1186/1751-0147-52-67
10.1093/annonc/mdq421
10.1038/bjc.2012.335
10.1016/j.lfs.2021.119431
10.1016/S1470-2045(17)30688-5
10.1016/S1470-2045(14)70320-1
10.1016/S0140-6736(16)32417-5
10.3390/ijms22020844
10.3322/caac.21708
10.1371/journal.pone.0229031
10.1016/S0140-6736(11)61847-3
10.1016/S1470-2045(14)71159-3
10.1016/S1470-2045(16)00106-6
10.3390/cancers13143517
10.1039/C9BM01766F
10.3389/fonc.2012.00062
10.1016/S0140-6736(12)61963-1
10.1016/S1470-2045(11)70336-9
10.1001/jamaoncol.2018.5152
10.1186/s12943-019-0954-x
10.20944/preprints201902.0245.v1
10.1200/JCO.2002.20.3.719
10.1056/NEJMoa1607303
10.1016/S1470-2045(19)30164-0
10.1200/JCO.2008.18.8391
10.1111/j.1939-1676.2011.0723.x
10.3390/jpm11100948
10.1186/bcr3039
10.1038/s41523-020-0153-3
10.1056/NEJMoa1903765
10.1016/S1470-2045(18)30292-4
10.1016/j.tvjl.2014.06.003
10.1371/journal.pone.0127381
10.1158/0008-5472.CAN-13-1197
10.1007/s13277-015-3661-2
10.3389/fvets.2021.623800
10.1146/annurev-med-070909-182917
10.1001/jamaoncol.2021.8171
10.1016/j.rvsc.2005.02.002
10.1016/j.tvjl.2010.08.012
10.1200/JCO.2011.39.0708
10.1056/NEJMoa040331
10.1038/sj.bjc.6602192
10.1158/1078-0432.CCR-13-2332
10.1093/annonc/mdw562
10.1354/vp.42-2-200
10.3390/cancers12041050
10.1038/aps.2015.71
10.1158/1535-7163.MCT-06-0423
10.1158/2159-8290.CD-17-1229
10.1021/acs.jmedchem.8b01492
10.1016/j.canlet.2012.09.017
10.1007/s10549-014-3037-0
10.1016/S1470-2045(19)30817-4
10.1016/j.ceb.2009.11.014
10.1016/j.cell.2017.04.001
10.1136/vr.133.22.539
10.1093/annonc/mdx002
10.1038/nature23465
10.1016/j.canlet.2005.01.041
10.1016/j.jsbmb.2005.02.004
10.1111/coa.13870
10.1016/S1470-2045(18)30241-9
10.1038/bjc.1988.138
10.1038/nrclinonc.2018.28
10.1056/NEJMoa1109653
10.2147/CE.S217848
10.3390/cancers13174287
10.1093/annonc/mdz133
10.1016/S0140-6736(04)17666-6
10.1200/JCO.2017.73.7585
10.1016/j.molcel.2015.10.040
10.1200/JCO.2006.09.5992
10.1038/bjc.1971.33
10.1200/JCO.2009.23.3734
10.1001/jamaoncol.2018.4475
10.3121/cmr.1.4.309
10.1016/S0960-0760(97)80010-6
10.1016/j.annonc.2020.11.011
10.3390/genes12081206
10.1056/NEJMoa1413513
10.3389/fonc.2021.693104
10.1093/annonc/mdu551
10.1093/jn/130.12.2927
10.1016/S1470-2045(20)30447-2
10.1186/bcr3069
10.1038/bjc.2013.178
10.1016/j.annonc.2020.08.2098
10.1056/NEJMoa1813904
10.1007/s40259-020-00446-7
10.1016/j.omtn.2020.12.018
10.7314/APJCP.2016.17.S3.43
10.1038/s41573-022-00579-0
10.3390/cancers11060737
10.1021/jm4003632
10.1016/j.beem.2003.08.002
10.1093/annonc/mdz381
10.1158/2159-8290.CD-16-1080
10.1200/JCO.2016.69.2871
10.1158/1078-0432.CCR-06-2540
10.1007/s00204-023-03440-4
10.1056/NEJMoa1505270
10.1158/1078-0432.CCR-17-0754
10.3390/ijms18061182
10.1016/j.canlet.2008.01.033
10.1200/JCO.2017.72.7107
10.1101/cshperspect.a016709
10.1091/mbc.e08-12-1248
10.1159/000499534
10.1056/NEJMoa1802905
10.1038/s41420-022-00893-x
10.1016/j.ccr.2004.06.022
10.1007/s10549-018-05125-4
10.1007/s12325-013-0060-1
10.1016/S1470-2045(17)30376-5
10.1136/vr.103398
10.1093/jnci/djk134
10.4314/ovj.v8i1.5
10.1126/science.aam7344
10.1056/NEJMoa1809615
10.2217/fon-2020-0464
10.1056/NEJMoa1911149
10.7554/eLife.12792
10.1074/jbc.M804612200
10.3390/curroncol29060337
10.1002/mc.22935
10.1056/NEJMoa1706450
10.3389/fgene.2015.00186
10.1007/s10549-017-4537-5
10.1158/0008-5472.CAN-12-2753
10.1177/0300985810393258
10.1177/0300985812447830
10.1016/j.jcpa.2014.04.001
10.1200/JCO.2018.36.18_suppl.LBA1006
10.1093/annonc/mdp304
10.1021/acsnano.6b06477
10.1056/NEJM200103153441101
10.1007/s10549-017-4542-8
10.1634/theoncologist.2009-0240
10.1056/NEJMoa1609709
10.7150/jca.33079
10.1016/j.bmcl.2021.128383
10.1200/JCO.2018.78.9909
10.1016/j.ccr.2007.08.030
10.1200/JCO.1998.16.10.3439
10.1093/annonc/mdy155
ContentType Journal Article
Copyright COPYRIGHT 2024 MDPI AG
2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: COPYRIGHT 2024 MDPI AG
– notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
DOI 10.3390/ijms25020732
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Research Library (ProQuest)
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
CrossRef
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1422-0067
ExternalDocumentID A780876411
38255807
10_3390_ijms25020732
Genre Systematic Review
Journal Article
GeographicLocations Canada
Taiwan
GeographicLocations_xml – name: Canada
– name: Taiwan
GroupedDBID ---
29J
2WC
53G
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
ESX
F5P
FRP
FYUFA
GNUQQ
GUQSH
GX1
HH5
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M2O
M48
MODMG
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RPM
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
K9.
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
ID FETCH-LOGICAL-c381t-5224f456581dbd15d3b5c2dcc0c8e6ffe646903fd14c0ea2e8c8cbf7c7e72813
IEDL.DBID M48
ISSN 1422-0067
1661-6596
IngestDate Fri Jul 11 09:43:28 EDT 2025
Fri Jul 25 08:00:56 EDT 2025
Tue Jun 17 22:21:34 EDT 2025
Tue Jun 10 21:19:15 EDT 2025
Mon Jul 21 06:08:27 EDT 2025
Tue Jul 01 02:23:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords targeted therapy
hormone therapy
canine mammary gland tumor
comparative oncology
Language English
License https://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c381t-5224f456581dbd15d3b5c2dcc0c8e6ffe646903fd14c0ea2e8c8cbf7c7e72813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
ObjectType-Review-4
content type line 23
ORCID 0000-0001-9602-9630
0000-0003-1911-7535
0000-0003-2254-8344
OpenAccessLink https://www.proquest.com/docview/2918768872?pq-origsite=%requestingapplication%
PMID 38255807
PQID 2918768872
PQPubID 2032341
ParticipantIDs proquest_miscellaneous_2917866180
proquest_journals_2918768872
gale_infotracmisc_A780876411
gale_infotracacademiconefile_A780876411
pubmed_primary_38255807
crossref_primary_10_3390_ijms25020732
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-01-01
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle International journal of molecular sciences
PublicationTitleAlternate Int J Mol Sci
PublicationYear 2024
Publisher MDPI AG
Publisher_xml – name: MDPI AG
References Garces (ref_92) 2019; 62
Ettl (ref_123) 2019; 14
Litton (ref_151) 2020; 31
Schmid (ref_52) 2020; 38
Dickler (ref_54) 2017; 23
Yang (ref_79) 2022; 29
Ghoncheh (ref_166) 2016; 17
ref_11
Costa (ref_73) 2020; 6
Molinaro (ref_156) 2020; 8
Chen (ref_8) 2019; 10
Lawson (ref_163) 2019; 58
Baselga (ref_97) 2017; 18
ref_17
Sledge (ref_137) 2017; 35
Juric (ref_109) 2017; 7
Nahta (ref_59) 2006; 232
Mansoori (ref_162) 2021; 276
Nguyen (ref_19) 2018; 167
Queiroga (ref_177) 2011; 25
Loibl (ref_55) 2017; 389
Baselga (ref_82) 2012; 379
Yu (ref_107) 2023; 97
Morris (ref_181) 1993; 133
Abdelmegeed (ref_12) 2018; 15
Siegel (ref_1) 2022; 72
Chow (ref_90) 2013; 108
Slamon (ref_134) 2020; 382
Goel (ref_125) 2017; 548
Finn (ref_127) 2016; 375
Dios (ref_178) 2005; 42
Mateo (ref_146) 2019; 30
Dirix (ref_154) 2018; 167
ref_122
Varallo (ref_169) 2019; 18
Robson (ref_148) 2017; 377
Zhou (ref_165) 2021; 23
Bang (ref_72) 2017; 28
Vuylsteke (ref_100) 2016; 27
Rugo (ref_77) 2017; 317
Yardley (ref_121) 2013; 30
ref_29
Szostakowska (ref_50) 2019; 173
ref_26
Millanta (ref_175) 2005; 79
Davies (ref_39) 2013; 381
Jeselsohn (ref_40) 2014; 20
Manning (ref_112) 2017; 169
Hortobagyi (ref_131) 2016; 375
Verret (ref_95) 2019; 30
Abadie (ref_171) 2018; 167
Clemente (ref_172) 2013; 50
Antonino (ref_161) 2022; 47
Yeheskel (ref_41) 2013; 73
Cristofanilli (ref_130) 2022; 28
ref_158
Osborne (ref_138) 2011; 62
Mainenti (ref_176) 2014; 202
Massarweh (ref_115) 2007; 13
Kim (ref_13) 2014; 151
Singer (ref_188) 2012; 50
Gianni (ref_70) 2012; 13
Smith (ref_37) 2017; 35
ref_155
Shen (ref_45) 2015; 7
Schwartzberg (ref_87) 2010; 15
Miller (ref_47) 2008; 283
ref_74
Krop (ref_99) 2016; 17
Geyer (ref_86) 2006; 355
Miller (ref_116) 2011; 13
Nagata (ref_64) 2004; 6
Schmid (ref_152) 2018; 379
George (ref_124) 2021; 11
Adams (ref_153) 2019; 5
Fossati (ref_24) 1998; 16
Litton (ref_150) 2018; 379
Sultan (ref_167) 2018; 8
Nordstrom (ref_71) 2011; 13
Hinz (ref_113) 2019; 17
Scaltriti (ref_61) 2007; 99
Nahta (ref_81) 2007; 6
Toniti (ref_179) 2009; 10
Kohler (ref_20) 2015; 107
Howell (ref_27) 2004; 18
Tripathy (ref_135) 2018; 19
Browne (ref_85) 2010; 9
ref_89
ref_142
Mamounas (ref_25) 2003; 1
Vu (ref_63) 2012; 2
Slamon (ref_57) 2001; 344
Goldschmidt (ref_15) 2011; 48
Bonnefoi (ref_84) 2015; 26
Han (ref_147) 2020; 21
Berns (ref_65) 2007; 12
Kang (ref_157) 2017; 11
Drebin (ref_67) 1988; 2
Baselga (ref_110) 2018; 36
Turner (ref_128) 2015; 373
Baselga (ref_119) 2009; 27
Coombes (ref_38) 2004; 350
Murai (ref_145) 2012; 72
Weng (ref_184) 2008; 262
Johnston (ref_88) 2009; 27
Slamon (ref_133) 2018; 36
Holmes (ref_83) 2014; 15
Colleoni (ref_78) 2018; 19
Wang (ref_108) 2015; 36
Alvarez (ref_75) 2020; 34
Simon (ref_173) 2006; 20
Janku (ref_96) 2018; 15
Deshmane (ref_28) 2007; 25
Chan (ref_91) 2016; 17
Pascual (ref_114) 2019; 30
Sorenmo (ref_168) 2009; 7
Mavratzas (ref_102) 2021; 17
Katoh (ref_160) 2013; 328
Robert (ref_22) 1997; 11
Reinert (ref_9) 2015; 7
Tremont (ref_4) 2017; 17
Finn (ref_129) 2015; 16
Swain (ref_10) 2023; 22
Sainsbury (ref_30) 2004; 91
Lord (ref_144) 2017; 355
Kim (ref_190) 2011; 189
Minuti (ref_60) 2012; 107
Ishii (ref_68) 2019; 14
Pivot (ref_76) 2022; 8
Schmid (ref_118) 2021; 81
Ellis (ref_94) 2019; 21
Bachelot (ref_53) 2012; 30
Keshaviah (ref_34) 2005; 353
Baselga (ref_56) 2010; 21
Pandiella (ref_62) 2022; 41
Chan (ref_51) 2017; 28
Howell (ref_31) 2005; 93
Ciruelos (ref_106) 2021; 32
Howell (ref_33) 2005; 365
Yip (ref_180) 2014; 10
Jones (ref_117) 2020; 21
Johnston (ref_98) 2018; 19
Fanning (ref_42) 2016; 5
Harada (ref_36) 1997; 61
Valladares (ref_35) 1979; 105
Arenas (ref_174) 2016; 179
Wei (ref_46) 2014; 147
Puyang (ref_43) 2018; 8
Kim (ref_170) 2020; 11
Sorenmo (ref_16) 2011; 48
Saxena (ref_139) 2010; 2
Konecny (ref_80) 2006; 66
Ndubaku (ref_111) 2013; 56
Jankowitz (ref_21) 2013; 27
Robson (ref_149) 2019; 30
Waks (ref_7) 2019; 321
Rugo (ref_126) 2019; 174
Tavares (ref_182) 2010; 52
Brisken (ref_2) 2015; 156
Kataoka (ref_66) 2010; 21
Yang (ref_48) 2010; 22
Hortobagyi (ref_132) 2018; 29
Swain (ref_69) 2015; 372
Yang (ref_93) 2019; 18
Falkenberg (ref_140) 2014; 13
(ref_143) 2015; 60
Meng (ref_183) 2000; 130
Moe (ref_14) 2001; 57
Juric (ref_104) 2019; 5
Cole (ref_23) 1971; 25
ref_44
Carpen (ref_164) 2022; 8
ref_185
Jiang (ref_141) 2019; 20
(ref_186) 2014; 29
Hosokawa (ref_49) 2009; 20
ref_101
ref_3
ref_191
Baum (ref_32) 2002; 359
Domingo (ref_187) 2011; 25
Vogel (ref_58) 2002; 20
Burrai (ref_189) 2015; 36
Juric (ref_103) 2018; 36
Ciruelos (ref_105) 2019; 380
ref_5
Valdivia (ref_18) 2021; 8
Im (ref_136) 2019; 381
Baselga (ref_120) 2012; 366
ref_6
Cammaerts (ref_159) 2015; 6
References_xml – volume: 156
  start-page: 3442
  year: 2015
  ident: ref_2
  article-title: Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis
  publication-title: Endocrinology
  doi: 10.1210/en.2015-1392
– volume: 17
  start-page: 367
  year: 2016
  ident: ref_91
  article-title: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(15)00551-3
– ident: ref_74
  doi: 10.1186/s12885-015-1583-4
– volume: 66
  start-page: 1630
  year: 2006
  ident: ref_80
  article-title: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-05-1182
– volume: 13
  start-page: 673
  year: 2014
  ident: ref_140
  article-title: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd4360
– volume: 81
  start-page: PD1-11
  year: 2021
  ident: ref_118
  article-title: Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.SABCS20-PD1-11
– volume: 30
  start-page: 1437
  year: 2019
  ident: ref_146
  article-title: A decade of clinical development of PARP inhibitors in perspective
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdz192
– ident: ref_11
  doi: 10.1186/s12917-021-03093-4
– volume: 107
  start-page: djv048
  year: 2015
  ident: ref_20
  article-title: Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djv048
– volume: 355
  start-page: 2733
  year: 2006
  ident: ref_86
  article-title: Lapatinib plus capecitabine for HER2-positive advanced breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa064320
– volume: 167
  start-page: 635
  year: 2018
  ident: ref_19
  article-title: Canine invasive mammary carcinomas as models of human breast cancer. Part 1: Natural history and prognostic factors
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4548-2
– volume: 359
  start-page: 2131
  year: 2002
  ident: ref_32
  article-title: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)09088-8
– volume: 11
  start-page: 3616
  year: 2020
  ident: ref_170
  article-title: Cross-species oncogenic signatures of breast cancer in canine mammary tumors
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-17458-0
– volume: 321
  start-page: 288
  year: 2019
  ident: ref_7
  article-title: Breast Cancer Treatment: A Review
  publication-title: JAMA
  doi: 10.1001/jama.2018.19323
– volume: 30
  start-page: 558
  year: 2019
  ident: ref_149
  article-title: OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdz012
– volume: 20
  start-page: 1184
  year: 2006
  ident: ref_173
  article-title: Postoperative Adjuvant Treatment of Invasive Malignant Mammary Gland Tumors in Dogs with Doxorubicin and Docetaxel
  publication-title: J. Vet. Intern. Med.
– volume: 48
  start-page: 85
  year: 2011
  ident: ref_16
  article-title: Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms
  publication-title: Vet. Pathol.
  doi: 10.1177/0300985810389480
– volume: 38
  start-page: 423
  year: 2020
  ident: ref_52
  article-title: Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.19.00368
– volume: 27
  start-page: 2059
  year: 2016
  ident: ref_100
  article-title: Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: Interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdw320
– volume: 317
  start-page: 37
  year: 2017
  ident: ref_77
  article-title: Effect of a Proposed Trastuzumab Biosimilar Compared with Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial
  publication-title: JAMA
  doi: 10.1001/jama.2016.18305
– volume: 17
  start-page: 154
  year: 2019
  ident: ref_113
  article-title: Distinct functions of AKT isoforms in breast cancer: A comprehensive review
  publication-title: Cell Commun. Signal
  doi: 10.1186/s12964-019-0450-3
– volume: 9
  start-page: 1489
  year: 2010
  ident: ref_85
  article-title: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-09-1171
– volume: 173
  start-page: 489
  year: 2019
  ident: ref_50
  article-title: Resistance to endocrine therapy in breast cancer: Molecular mechanisms and future goals
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-018-5023-4
– volume: 7
  start-page: 162
  year: 2009
  ident: ref_168
  article-title: Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence
  publication-title: Vet. Comp. Oncol.
  doi: 10.1111/j.1476-5829.2009.00184.x
– volume: 21
  start-page: 110
  year: 2019
  ident: ref_94
  article-title: PI3K Inhibitors in Breast Cancer Therapy
  publication-title: Curr. Oncol. Rep.
  doi: 10.1007/s11912-019-0846-7
– volume: 50
  start-page: 200
  year: 2012
  ident: ref_188
  article-title: Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2012.01.002
– ident: ref_185
  doi: 10.1186/s12885-018-4518-z
– volume: 10
  start-page: 2293
  year: 2014
  ident: ref_180
  article-title: Estrogen and progesterone receptors in breast cancer
  publication-title: Future Oncol.
  doi: 10.2217/fon.14.110
– volume: 7
  start-page: 304
  year: 2015
  ident: ref_9
  article-title: Optimal management of hormone receptor positive metastatic breast cancer in 2016
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/1758834015608993
– volume: 105
  start-page: 431
  year: 1979
  ident: ref_35
  article-title: Induction of testicular aromatization by luteinizing hormone in mature rats
  publication-title: Endocrinology
  doi: 10.1210/endo-105-2-431
– volume: 353
  start-page: 2747
  year: 2005
  ident: ref_34
  article-title: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa052258
– volume: 41
  start-page: 310
  year: 2022
  ident: ref_62
  article-title: HER3 in cancer: From the bench to the bedside
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-022-02515-x
– volume: 28
  start-page: 3433
  year: 2022
  ident: ref_130
  article-title: Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-22-0305
– volume: 52
  start-page: 67
  year: 2010
  ident: ref_182
  article-title: Evaluation of adverse effects in tamoxifen exposed healthy female dogs
  publication-title: Acta Vet. Scand.
  doi: 10.1186/1751-0147-52-67
– volume: 21
  start-page: vii36
  year: 2010
  ident: ref_56
  article-title: Treatment of HER2-overexpressing breast cancer
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdq421
– volume: 107
  start-page: 793
  year: 2012
  ident: ref_60
  article-title: Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2012.335
– volume: 276
  start-page: 119431
  year: 2021
  ident: ref_162
  article-title: MiR-142-3p targets HMGA2 and suppresses breast cancer malignancy
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2021.119431
– volume: 19
  start-page: 87
  year: 2018
  ident: ref_98
  article-title: Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30688-5
– volume: 15
  start-page: 1137
  year: 2014
  ident: ref_83
  article-title: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(14)70320-1
– volume: 389
  start-page: 2415
  year: 2017
  ident: ref_55
  article-title: HER2-positive breast cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32417-5
– ident: ref_155
  doi: 10.3390/ijms22020844
– volume: 72
  start-page: 7
  year: 2022
  ident: ref_1
  article-title: Cancer statistics, 2022
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21708
– ident: ref_191
  doi: 10.1371/journal.pone.0229031
– volume: 379
  start-page: 633
  year: 2012
  ident: ref_82
  article-title: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)61847-3
– volume: 16
  start-page: 25
  year: 2015
  ident: ref_129
  article-title: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(14)71159-3
– volume: 17
  start-page: 811
  year: 2016
  ident: ref_99
  article-title: Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)00106-6
– ident: ref_101
  doi: 10.3390/cancers13143517
– volume: 8
  start-page: 333
  year: 2020
  ident: ref_156
  article-title: Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma
  publication-title: Biomater. Sci.
  doi: 10.1039/C9BM01766F
– volume: 2
  start-page: 62
  year: 2012
  ident: ref_63
  article-title: Trastuzumab: Updated mechanisms of action and resistance in breast cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2012.00062
– volume: 381
  start-page: 805
  year: 2013
  ident: ref_39
  article-title: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)61963-1
– volume: 13
  start-page: 25
  year: 2012
  ident: ref_70
  article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(11)70336-9
– volume: 5
  start-page: 334
  year: 2019
  ident: ref_153
  article-title: Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer with 2-Year Survival Follow-up: A Phase 1b Clinical Trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.5152
– volume: 18
  start-page: 26
  year: 2019
  ident: ref_93
  article-title: Targeting PI3K in cancer: Mechanisms and advances in clinical trials
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-0954-x
– ident: ref_122
  doi: 10.20944/preprints201902.0245.v1
– volume: 11
  start-page: 15
  year: 1997
  ident: ref_22
  article-title: Clinical efficacy of tamoxifen
  publication-title: Oncology
– volume: 20
  start-page: 719
  year: 2002
  ident: ref_58
  article-title: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2002.20.3.719
– volume: 375
  start-page: 1925
  year: 2016
  ident: ref_127
  article-title: Palbociclib and Letrozole in Advanced Breast Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1607303
– volume: 20
  start-page: 806
  year: 2019
  ident: ref_141
  article-title: Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): A randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30164-0
– volume: 27
  start-page: 2630
  year: 2009
  ident: ref_119
  article-title: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.18.8391
– volume: 25
  start-page: 518
  year: 2011
  ident: ref_187
  article-title: Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas
  publication-title: J. Vet. Intern. Med.
  doi: 10.1111/j.1939-1676.2011.0723.x
– ident: ref_5
  doi: 10.3390/jpm11100948
– volume: 13
  start-page: 224
  year: 2011
  ident: ref_116
  article-title: Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer
  publication-title: Breast Cancer Res.
  doi: 10.1186/bcr3039
– volume: 6
  start-page: 10
  year: 2020
  ident: ref_73
  article-title: Clinical development of immunotherapies for HER2+ breast cancer: A review of HER2-directed monoclonal antibodies and beyond
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-020-0153-3
– volume: 381
  start-page: 307
  year: 2019
  ident: ref_136
  article-title: Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1903765
– volume: 19
  start-page: 904
  year: 2018
  ident: ref_135
  article-title: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30292-4
– volume: 202
  start-page: 62
  year: 2014
  ident: ref_176
  article-title: Oestrogen and progesterone receptor expression in subtypes of canine mammary tumours in intact and ovariectomised dogs
  publication-title: Vet. J.
  doi: 10.1016/j.tvjl.2014.06.003
– ident: ref_17
  doi: 10.1371/journal.pone.0127381
– volume: 73
  start-page: 6856
  year: 2013
  ident: ref_41
  article-title: D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-1197
– volume: 29
  start-page: 949
  year: 2014
  ident: ref_186
  article-title: The antiprogestins mifepristone and onapristone reduce cell proliferation in the canine mammary carcinoma cell line CMT-U27
  publication-title: Histol. Histopathol.
– volume: 36
  start-page: 9083
  year: 2015
  ident: ref_189
  article-title: Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: Is the dog a suitable animal model for human breast cancer?
  publication-title: Tumour Biol.
  doi: 10.1007/s13277-015-3661-2
– volume: 8
  start-page: 623800
  year: 2021
  ident: ref_18
  article-title: From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
  publication-title: Front. Vet. Sci.
  doi: 10.3389/fvets.2021.623800
– volume: 62
  start-page: 233
  year: 2011
  ident: ref_138
  article-title: Mechanisms of endocrine resistance in breast cancer
  publication-title: Annu. Rev. Med.
  doi: 10.1146/annurev-med-070909-182917
– volume: 8
  start-page: 698
  year: 2022
  ident: ref_76
  article-title: Efficacy of HD201 vs Referent Trastuzumab in Patients with ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2021.8171
– volume: 79
  start-page: 225
  year: 2005
  ident: ref_175
  article-title: Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues
  publication-title: Res. Vet. Sci.
  doi: 10.1016/j.rvsc.2005.02.002
– volume: 189
  start-page: 318
  year: 2011
  ident: ref_190
  article-title: Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: Histopathological and immunohistochemical study
  publication-title: Vet. J.
  doi: 10.1016/j.tvjl.2010.08.012
– volume: 30
  start-page: 2718
  year: 2012
  ident: ref_53
  article-title: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.39.0708
– volume: 350
  start-page: 1081
  year: 2004
  ident: ref_38
  article-title: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa040331
– volume: 91
  start-page: 1754
  year: 2004
  ident: ref_30
  article-title: The Breast: Comprehensive Management of Benign and Malignant Disorders
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6602192
– volume: 20
  start-page: 1757
  year: 2014
  ident: ref_40
  article-title: Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-2332
– volume: 28
  start-page: 313
  year: 2017
  ident: ref_51
  article-title: A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdw562
– volume: 42
  start-page: 200
  year: 2005
  ident: ref_178
  article-title: A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog
  publication-title: Vet. Pathol.
  doi: 10.1354/vp.42-2-200
– ident: ref_142
  doi: 10.3390/cancers12041050
– volume: 17
  start-page: 405
  year: 2017
  ident: ref_4
  article-title: Endocrine Therapy for Early Breast Cancer: Updated Review
  publication-title: Ochsner J.
– volume: 36
  start-page: 1170
  year: 2015
  ident: ref_108
  article-title: PI3K isoform-selective inhibitors: Next-generation targeted cancer therapies
  publication-title: Acta Pharmacol. Sin.
  doi: 10.1038/aps.2015.71
– volume: 6
  start-page: 667
  year: 2007
  ident: ref_81
  article-title: Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-06-0423
– volume: 15
  start-page: 8195
  year: 2018
  ident: ref_12
  article-title: Canine mammary tumors as a model for human disease (Review)
  publication-title: Oncol. Lett.
– volume: 8
  start-page: 1176
  year: 2018
  ident: ref_43
  article-title: Discovery of selective estrogen receptor covalent antagonists for the treatment of ERαWT and ERαMUT breast cancer
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-17-1229
– volume: 62
  start-page: 4815
  year: 2019
  ident: ref_92
  article-title: Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01492
– volume: 328
  start-page: 198
  year: 2013
  ident: ref_160
  article-title: Cancer genetics and genomics of human FOX family genes
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2012.09.017
– volume: 147
  start-page: 423
  year: 2014
  ident: ref_46
  article-title: Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-014-3037-0
– volume: 21
  start-page: 345
  year: 2020
  ident: ref_117
  article-title: Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): A multicentre, randomised, controlled, phase 2 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30817-4
– volume: 57
  start-page: 439
  year: 2001
  ident: ref_14
  article-title: Population-based incidence of mammary tumours in some dog breeds
  publication-title: J. Reprod. Fertil. Suppl.
– volume: 22
  start-page: 124
  year: 2010
  ident: ref_48
  article-title: Mammalian autophagy: Core molecular machinery and signaling regulation
  publication-title: Curr. Opin. Cell Biol.
  doi: 10.1016/j.ceb.2009.11.014
– volume: 169
  start-page: 381
  year: 2017
  ident: ref_112
  article-title: AKT/PKB Signaling: Navigating the Network
  publication-title: Cell
  doi: 10.1016/j.cell.2017.04.001
– volume: 133
  start-page: 539
  year: 1993
  ident: ref_181
  article-title: Use of tamoxifen in the control of canine mammary neoplasia
  publication-title: Vet. Rec.
  doi: 10.1136/vr.133.22.539
– volume: 28
  start-page: 855
  year: 2017
  ident: ref_72
  article-title: First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx002
– volume: 548
  start-page: 471
  year: 2017
  ident: ref_125
  article-title: CDK4/6 inhibition triggers anti-tumour immunity
  publication-title: Nature
  doi: 10.1038/nature23465
– volume: 232
  start-page: 123
  year: 2006
  ident: ref_59
  article-title: Herceptin: Mechanisms of action and resistance
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2005.01.041
– volume: 93
  start-page: 237
  year: 2005
  ident: ref_31
  article-title: Are aromatase inhibitors superior to antiestrogens?
  publication-title: J. Steroid Biochem. Mol. Biol.
  doi: 10.1016/j.jsbmb.2005.02.004
– volume: 47
  start-page: 14
  year: 2022
  ident: ref_161
  article-title: Single-nucleotide polymorphism in chronic rhinosinusitis: A systematic review
  publication-title: Clin. Otolaryngol.
  doi: 10.1111/coa.13870
– volume: 19
  start-page: 987
  year: 2018
  ident: ref_78
  article-title: Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): A randomised, double-blind, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30241-9
– ident: ref_26
  doi: 10.1038/bjc.1988.138
– volume: 15
  start-page: 273
  year: 2018
  ident: ref_96
  article-title: Targeting the PI3K pathway in cancer: Are we making headway?
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2018.28
– volume: 2
  start-page: 191
  year: 2010
  ident: ref_139
  article-title: Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy
  publication-title: Mol. Cell Pharmacol.
– volume: 366
  start-page: 520
  year: 2012
  ident: ref_120
  article-title: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1109653
– volume: 14
  start-page: 51
  year: 2019
  ident: ref_68
  article-title: Pertuzumab in the treatment of HER2-positive breast cancer: An evidence-based review of its safety, efficacy, and place in therapy
  publication-title: Core Evid.
  doi: 10.2147/CE.S217848
– ident: ref_6
  doi: 10.3390/cancers13174287
– volume: 30
  start-page: 1051
  year: 2019
  ident: ref_114
  article-title: Targeting the PI3-kinase pathway in triple-negative breast cancer
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdz133
– volume: 365
  start-page: 60
  year: 2005
  ident: ref_33
  article-title: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)17666-6
– volume: 35
  start-page: 2875
  year: 2017
  ident: ref_137
  article-title: MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.73.7585
– volume: 60
  start-page: 547
  year: 2015
  ident: ref_143
  article-title: Targeting the DNA Damage Response in Cancer
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2015.10.040
– volume: 25
  start-page: 4967
  year: 2007
  ident: ref_28
  article-title: Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2006.09.5992
– volume: 25
  start-page: 270
  year: 1971
  ident: ref_23
  article-title: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.1971.33
– volume: 27
  start-page: 5538
  year: 2009
  ident: ref_88
  article-title: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2009.23.3734
– volume: 5
  start-page: e184475
  year: 2019
  ident: ref_104
  article-title: Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.4475
– volume: 1
  start-page: 309
  year: 2003
  ident: ref_25
  article-title: NSABP breast cancer clinical trials: Recent results and future directions
  publication-title: Clin. Med. Res.
  doi: 10.3121/cmr.1.4.309
– volume: 61
  start-page: 175
  year: 1997
  ident: ref_36
  article-title: Aberrant expression of aromatase in breast cancer tissues
  publication-title: J. Steroid Biochem. Mol. Biol.
  doi: 10.1016/S0960-0760(97)80010-6
– volume: 32
  start-page: 208
  year: 2021
  ident: ref_106
  article-title: Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Final overall survival results from SOLAR-1
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1016/j.annonc.2020.11.011
– ident: ref_158
  doi: 10.3390/genes12081206
– volume: 372
  start-page: 724
  year: 2015
  ident: ref_69
  article-title: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1413513
– volume: 11
  start-page: 693104
  year: 2021
  ident: ref_124
  article-title: Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2021.693104
– volume: 26
  start-page: 325
  year: 2015
  ident: ref_84
  article-title: Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: Results of the randomised phase II EORTC 10054 study
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdu551
– volume: 130
  start-page: 2927
  year: 2000
  ident: ref_183
  article-title: Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells
  publication-title: J. Nutr.
  doi: 10.1093/jn/130.12.2927
– volume: 21
  start-page: 1269
  year: 2020
  ident: ref_147
  article-title: Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): A randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30447-2
– volume: 13
  start-page: R123
  year: 2011
  ident: ref_71
  article-title: Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
  publication-title: Breast Cancer Res.
  doi: 10.1186/bcr3069
– volume: 108
  start-page: 1985
  year: 2013
  ident: ref_90
  article-title: Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2013.178
– volume: 31
  start-page: 1526
  year: 2020
  ident: ref_151
  article-title: Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: Final overall survival results from the EMBRACA trial
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1016/j.annonc.2020.08.2098
– volume: 380
  start-page: 1929
  year: 2019
  ident: ref_105
  article-title: Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1813904
– volume: 34
  start-page: 723
  year: 2020
  ident: ref_75
  article-title: Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
  publication-title: BioDrugs
  doi: 10.1007/s40259-020-00446-7
– volume: 23
  start-page: 682
  year: 2021
  ident: ref_165
  article-title: Single-cell RNA-seq dissects the intratumoral heterogeneity of triple-negative breast cancer based on gene regulatory networks
  publication-title: Mol. Ther. Nucleic Acids
  doi: 10.1016/j.omtn.2020.12.018
– volume: 17
  start-page: 43
  year: 2016
  ident: ref_166
  article-title: Incidence and Mortality and Epidemiology of Breast Cancer in the World
  publication-title: Asian Pac. J. Cancer Prev.
  doi: 10.7314/APJCP.2016.17.S3.43
– volume: 22
  start-page: 101
  year: 2023
  ident: ref_10
  article-title: Targeting HER2-positive breast cancer: Advances and future directions
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-022-00579-0
– ident: ref_89
  doi: 10.3390/cancers11060737
– volume: 56
  start-page: 4597
  year: 2013
  ident: ref_111
  article-title: Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo [1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity
  publication-title: J. Med. Chem.
  doi: 10.1021/jm4003632
– volume: 18
  start-page: 47
  year: 2004
  ident: ref_27
  article-title: The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer
  publication-title: Best. Pract. Res. Clin. Endocrinol. Metab.
  doi: 10.1016/j.beem.2003.08.002
– volume: 30
  start-page: x12
  year: 2019
  ident: ref_95
  article-title: Efficacy of PI3K inhibitors in advanced breast cancer
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdz381
– volume: 7
  start-page: 704
  year: 2017
  ident: ref_109
  article-title: Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-16-1080
– volume: 35
  start-page: 1041
  year: 2017
  ident: ref_37
  article-title: Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients with Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.69.2871
– volume: 13
  start-page: 1950
  year: 2007
  ident: ref_115
  article-title: Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-2540
– volume: 97
  start-page: 635
  year: 2023
  ident: ref_107
  article-title: Development and safety of PI3K inhibitors in cancer
  publication-title: Arch. Toxicol.
  doi: 10.1007/s00204-023-03440-4
– volume: 373
  start-page: 209
  year: 2015
  ident: ref_128
  article-title: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1505270
– volume: 27
  start-page: 1210
  year: 2013
  ident: ref_21
  article-title: Adjuvant endocrine therapy for breast cancer: How long is long enough?
  publication-title: Oncology
– volume: 23
  start-page: 5218
  year: 2017
  ident: ref_54
  article-title: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-0754
– ident: ref_44
  doi: 10.3390/ijms18061182
– volume: 262
  start-page: 153
  year: 2008
  ident: ref_184
  article-title: Indole-3-carbinol as a chemopreventive and anti-cancer agent
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2008.01.033
– volume: 36
  start-page: 1291
  year: 2018
  ident: ref_103
  article-title: Phosphatidylinositol 3-Kinase α-Selective Inhibition with Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.72.7107
– ident: ref_3
  doi: 10.1101/cshperspect.a016709
– volume: 20
  start-page: 1981
  year: 2009
  ident: ref_49
  article-title: Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy
  publication-title: Mol. Biol. Cell
  doi: 10.1091/mbc.e08-12-1248
– volume: 14
  start-page: 86
  year: 2019
  ident: ref_123
  article-title: Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
  publication-title: Breast Care
  doi: 10.1159/000499534
– volume: 379
  start-page: 753
  year: 2018
  ident: ref_150
  article-title: Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1802905
– volume: 8
  start-page: 106
  year: 2022
  ident: ref_164
  article-title: A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies
  publication-title: Cell Death Discov.
  doi: 10.1038/s41420-022-00893-x
– volume: 10
  start-page: 907
  year: 2009
  ident: ref_179
  article-title: Immunohistochemical determination of estrogen and progesterone receptors in canine mammary tumors
  publication-title: Asian Pac. J. Cancer Prev.
– volume: 6
  start-page: 117
  year: 2004
  ident: ref_64
  article-title: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2004.06.022
– volume: 174
  start-page: 719
  year: 2019
  ident: ref_126
  article-title: Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-018-05125-4
– volume: 30
  start-page: 870
  year: 2013
  ident: ref_121
  article-title: Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis
  publication-title: Adv. Ther.
  doi: 10.1007/s12325-013-0060-1
– volume: 18
  start-page: 904
  year: 2017
  ident: ref_97
  article-title: Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30376-5
– volume: 179
  start-page: 125
  year: 2016
  ident: ref_174
  article-title: Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: A case-control prospective study
  publication-title: Vet. Rec.
  doi: 10.1136/vr.103398
– volume: 99
  start-page: 628
  year: 2007
  ident: ref_61
  article-title: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djk134
– volume: 8
  start-page: 25
  year: 2018
  ident: ref_167
  article-title: Comparative oncology: Integrating human and veterinary medicine
  publication-title: Open Vet. J.
  doi: 10.4314/ovj.v8i1.5
– volume: 18
  start-page: 6545
  year: 2019
  ident: ref_169
  article-title: Prognostic phenotypic classification for canine mammary tumors
  publication-title: Oncol. Lett.
– volume: 355
  start-page: 1152
  year: 2017
  ident: ref_144
  article-title: PARP inhibitors: Synthetic lethality in the clinic
  publication-title: Science
  doi: 10.1126/science.aam7344
– volume: 379
  start-page: 2108
  year: 2018
  ident: ref_152
  article-title: Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1809615
– volume: 2
  start-page: 273
  year: 1988
  ident: ref_67
  article-title: Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo
  publication-title: Oncogene
– volume: 17
  start-page: 13
  year: 2021
  ident: ref_102
  article-title: Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations
  publication-title: Future Oncol.
  doi: 10.2217/fon-2020-0464
– volume: 382
  start-page: 514
  year: 2020
  ident: ref_134
  article-title: Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1911149
– volume: 5
  start-page: e12792
  year: 2016
  ident: ref_42
  article-title: Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
  publication-title: eLife
  doi: 10.7554/eLife.12792
– volume: 283
  start-page: 29897
  year: 2008
  ident: ref_47
  article-title: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M804612200
– volume: 29
  start-page: 4224
  year: 2022
  ident: ref_79
  article-title: A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
  publication-title: Curr. Oncol.
  doi: 10.3390/curroncol29060337
– volume: 58
  start-page: 376
  year: 2019
  ident: ref_163
  article-title: Extracellular vesicle secretion of miR-142-3p from lung adenocarcinoma cells induces tumor promoting changes in the stroma through cell-cell communication
  publication-title: Mol. Carcinog.
  doi: 10.1002/mc.22935
– volume: 377
  start-page: 523
  year: 2017
  ident: ref_148
  article-title: Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1706450
– volume: 6
  start-page: 186
  year: 2015
  ident: ref_159
  article-title: Genetic variants in microRNA genes: Impact on microRNA expression, function, and disease
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2015.00186
– volume: 167
  start-page: 671
  year: 2018
  ident: ref_154
  article-title: Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN Solid Tumor study
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4537-5
– volume: 72
  start-page: 5588
  year: 2012
  ident: ref_145
  article-title: Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-2753
– volume: 48
  start-page: 117
  year: 2011
  ident: ref_15
  article-title: Classification and grading of canine mammary tumors
  publication-title: Vet. Pathol.
  doi: 10.1177/0300985810393258
– volume: 50
  start-page: 94
  year: 2013
  ident: ref_172
  article-title: Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: Relationship with clinical and histological characteristics
  publication-title: Vet. Pathol.
  doi: 10.1177/0300985812447830
– volume: 151
  start-page: 42
  year: 2014
  ident: ref_13
  article-title: Evaluation of clinicopathological characteristics and oestrogen receptor gene expression in oestrogen receptor-negative, progesterone receptor-positive canine mammary carcinomas
  publication-title: J. Comp. Pathol.
  doi: 10.1016/j.jcpa.2014.04.001
– volume: 36
  start-page: LBA1006
  year: 2018
  ident: ref_110
  article-title: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2018.36.18_suppl.LBA1006
– volume: 21
  start-page: 255
  year: 2010
  ident: ref_66
  article-title: Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdp304
– volume: 11
  start-page: 1397
  year: 2017
  ident: ref_157
  article-title: Nanoparticles Coated with Neutrophil Membranes Can Effectively Treat Cancer Metastasis
  publication-title: ACS Nano
  doi: 10.1021/acsnano.6b06477
– volume: 344
  start-page: 783
  year: 2001
  ident: ref_57
  article-title: Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM200103153441101
– volume: 167
  start-page: 459
  year: 2018
  ident: ref_171
  article-title: Canine invasive mammary carcinomas as models of human breast cancer. Part 2: Immunophenotypes and prognostic significance
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4542-8
– volume: 15
  start-page: 122
  year: 2010
  ident: ref_87
  article-title: Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0240
– volume: 25
  start-page: 455
  year: 2011
  ident: ref_177
  article-title: Canine mammary tumours as a model to study human breast cancer: Most recent findings
  publication-title: In Vivo
– volume: 375
  start-page: 1738
  year: 2016
  ident: ref_131
  article-title: Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1609709
– volume: 10
  start-page: 6608
  year: 2019
  ident: ref_8
  article-title: Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future
  publication-title: J. Cancer
  doi: 10.7150/jca.33079
– ident: ref_29
  doi: 10.1016/j.bmcl.2021.128383
– volume: 36
  start-page: 2465
  year: 2018
  ident: ref_133
  article-title: Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2018.78.9909
– volume: 12
  start-page: 395
  year: 2007
  ident: ref_65
  article-title: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2007.08.030
– volume: 16
  start-page: 3439
  year: 1998
  ident: ref_24
  article-title: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.1998.16.10.3439
– volume: 7
  start-page: 2115
  year: 2015
  ident: ref_45
  article-title: MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer
  publication-title: Am. J. Transl. Res.
– volume: 29
  start-page: 1541
  year: 2018
  ident: ref_132
  article-title: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdy155
SSID ssj0023259
Score 2.4029827
SecondaryResourceType review_article
Snippet Breast cancer (BC) is the most frequent cancer in women. In female dogs, canine mammary gland tumor (CMT) is also the leading neoplasm. Comparative oncology...
SourceID proquest
gale
pubmed
crossref
SourceType Aggregation Database
Index Database
StartPage 732
SubjectTerms Animals
Antibodies, Monoclonal - therapeutic use
Antimitotic agents
Antineoplastic agents
Autophagy
Biological products
Breast cancer
Breast Neoplasms - drug therapy
Canada
Cancer
Cancer therapies
Care and treatment
Clinical trials
Combined Modality Therapy
Comparative analysis
Development and progression
Dogs
Drug resistance
Endocrine therapy
Endometrial cancer
Estrogens
Female
Females
Health aspects
Hormones
Human acts
Human behavior
Humans
Kinases
Ligands
Monoclonal antibodies
Mortality
Oncology
Prospective Studies
Steroid hormones
Steroids
Taiwan
Toxicity
Tumors
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB6VVkhcEJRXoFSuRMWlUWMnjr1cUFtYrZDoaUF7i5KxjUBqUjbpgX_PjJNt2R44x0mseXi-bzKZAXinHZGARhZpqA0TFJeltTKYWi6zKKSdlbFl_tfLcvGt-LLSqynh1k9llZszMR7UrkPOkZ-qmSTHJZdQH69_pzw1ir-uTiM0HsAety7jki6zuiNcuYrD0iTFoLTUs3IsfM-J5p_-_HXVU_RXZOFqKyTdP5jvwc0YduZP4PGEF8XZqOCnsOPbfXg4TpD88wy-Lwhzdq0_EctY0u3diahbJ8jNifJOiT6xjD9ZEScWBFHFOdehD-KC9b3uP4j5ursSMZnfi6ETn7of_XNYzj8vLxbpNCohRQq5A9FJVQQGZwQ_Gye1yxuNyiFmaH0Zgi-ZBufByQIzXytv0WITDBpvlJX5C9htabOvQBRKuhqDdqixCBnWFOVyk_Pol5nXGBI43giruh4bYlREJFio1b9CTeA9S7JiPxnWNdZTuT-9hTtOVWfGcje8QsoEDrZWkn3j9uWNLqrJv_rqzhoSOLq9zHdyzVjru5u4xlhSvc0SeDnq8HbHORFjbTPz-v8PfwOPFIGYMeVyALvD-sa_JRAyNIfR0v4C547YCg
  priority: 102
  providerName: ProQuest
Title Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs
URI https://www.ncbi.nlm.nih.gov/pubmed/38255807
https://www.proquest.com/docview/2918768872
https://www.proquest.com/docview/2917866180
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEB7ShEIvoe9skywqtPQSp5YsrbSFUJI026WQUMom7M3YeoSWxG5sB5p_3xnbu3TTHnrxRRKSZ6SZ75PHMwBvlEMSkHMZhUwTQXFxlAltI0NhFpKb8ahNmX96Npqeyy9zNV-DRbXRXoD1P6kd1ZM6r672f93cfcQDf0CMEyn7--8_rmv05AJ3KxrjDfRJmo7oqVx-T0DY0JZNowuPiAx0FwL_1-gV53TfRN8Dnq0DmjyGzR45ssNO1U9gzRdP4WFXS_LuGVxMEX2Whd9jsza427s9lhWO4YFH8ttf-bFZ-7sVsmOGYJUdUUR6w45J81X9gU2q8pq11_o1a0r2qbysn8NscjI7nkZ90YTIovNtkFgKGQimIRDNHVcuyZUVztrYGj8KwY-IECfBcWljnwlvrLF50FZ7LQxPXsB6gYvdAiYFd5kNylllZYhthv4u0QkVgRl7ZcMA3i6Elf7sUmOkSClIqOmfQh3AO5JkSjpsqsxmfeA_zkK5p9JDbSgvnuR8ADsrPXGn29XmhS7SxUZJxZhjK5pKnOf1splGUvRY4cvbto82CERMPICXnQ6XK06QIisT61f_-Tbb8EggruluYXZgvalu_S7ikiYfwgM91_g0k89D2Dg6Ofv6bUieQg3bzfgbUPThdQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgQXxLMEChiJikujxnYSO0gIlZbVlj5OAe0tSmwHgdSkbFKh_ij-IzNO0rI9cOvZjmPNw_N99tgD8DaxSAIqHod1qYig2CgshTKhpjSLmOss9U_mH5-k86_xl0WyWIM_010YSquc1kS_UNvW0B75jsg4Oi66hPh49iukqlF0ujqV0BjM4tBd_EbK1n042Ef9bgkx-5zvzcOxqkBoMDr1yLxEXBOOQaRWWZ5YWSVGWGMio11a1y4lxihry2MTuVI4bbSpamWUU0JzicPegtsYdyNyKLW44ndS-NpsHENemCZZOuTZS5lFOz9-nnYINgQ6lFiJgNfjwDV066Pc7AHcH-Ep2x3s6SGsueYR3BkKVl48hm9zhLht47ZZ7jPInd1mZWMZrirIsMd9RZb7O11IwRkiYvaJ0t57tkfmtezes9myPWX-7KBjfcv22-_dE8hvQoZPYb3ByT4DFgtuS1Mn1iQmriNTYlCVSlKlmcwlpg5gaxJWcTa8v1EgbyGhFv8KNYB3JMmC3LJflqYcbxfgX-iBq2JXaXp8L-Y8gM2VnuhOZrV50kUxunNXXBlfAG8um-lLSlFrXHvu-yiNqtdRABuDDi9nLJGHJzpSz_8_-Gu4O8-Pj4qjg5PDF3BPIH4adns2Yb1fnruXiH_66pW3OgbFDVv5X7mLFXY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIhAXxJtAASNRcWm0sR3HDhJCpctqS6HisKC9WYkfqJWalE0q1J_Gv2OcR8v2wK1nO441D8_32WMPwBthkQSUNI19IQNBsUlcMGliFdIsUqryrHsy_-thNv-efl6K5Qb8Ge_ChLTKcU3sFmpbm7BHPmE5RcdFl2ATP6RFfJvOPpz-ikMFqXDSOpbT6E3kwJ3_RvrWvN-foq63GZt9WuzN46HCQGwwUrXIwljqA6ZB1FZaKiwvhWHWmMQol3nvssAeubc0NYkrmFNGmdJLI51kinIc9gbclFzQ4GJyecn1OOvqtFEMf3Em8qzPuec8TyZHxycNAg-GzsXWouHVmHAF6XYRb3YP7g5Qlez2tnUfNlz1AG71xSvPH8KPOcLdunI7ZNFlkzu7Q4rKElxhkG0Pe4xk0d3vQjpOEB2TjyEFviV7wdRWzTsyW9UnpDtHaEhbk2n9s3kEi-uQ4WPYrHCyT4GkjNrCeGGNMKlPTIEBlkseqs7kThgfwfYoLH3av8WhkcMEoep_hRrB2yBJHVy0XRWmGG4a4F_CY1d6V6rwEF9KaQRbaz3Rtcx686gLPbh2oy8NMYLXF83hy5CuVrn6rOsjFapeJRE86XV4MWOOnFyoRD77_-Cv4Dbat_6yf3jwHO4whFL9xs8WbLarM_cCoVBbvuyMjoC-ZiP_C4QBGaw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hormone%2C+Targeted%2C+and+Combinational+Therapies+for+Breast+Cancers%3A+From+Humans+to+Dogs&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Ke%2C+Chiao-Hsu&rft.au=Lin%2C+Chao-Nan&rft.au=Lin%2C+Chen-Si&rft.date=2024-01-01&rft.issn=1422-0067&rft.eissn=1422-0067&rft.volume=25&rft.issue=2&rft.spage=732&rft_id=info:doi/10.3390%2Fijms25020732&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_ijms25020732
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon